Lyka Labs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lyka Labs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 16% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 88% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash paid for 25% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares. Lower than 87% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.2×Over the last 3 years its own operating cash paid for 25% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 87% of Healthcare companies in India.
Cash Locked Ratio
₹25For every ₹100 of sales, ₹25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹11 tied up three years earlier.
More money tied up than 53% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹8Sales grew 45% in 3 years; of every extra ₹100 of sales, ₹8 became extra profit.
Lower than 73% of Healthcare companies in India.
Asset Productivity Ratio
+45% / +15%In 3 years sales changed by +45% while total assets changed by +15%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.2×Debt due within a year is covered 0.2 times by its yearly operating cash.
Lower than 84% of Healthcare companies in India.
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 84% of Healthcare companies in India.
Tangible Assets Ratio
96%Of every ₹100 the company owns, ₹96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 56% of Healthcare companies in India.
Tangible Net Worth Ratio
93%Of every ₹100 of net worth, ₹93 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 58% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Lyka Labs Limited made a loss over the last year. Lyka Labs Limited owes ₹0.48 for every ₹1 it owns. Lyka Labs Limited made a loss in the year to Mar 2026, after a profit the year before.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossLyka Labs Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.17The share price is 3.17 times Lyka Labs Limited's book value per share, lower than 67% of Healthcare companies in India.
Market cap
₹293 CrThe total market value of all of Lyka Labs Limited's shares at today's price (share price × number of shares), smaller than 90% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹92 CrWhat Lyka Labs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹25.56Net worth divided by the number of shares. The share price of ₹80.99 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
-9.7%Lyka Labs Limited lost 9.7% of its shareholders' money over the last year, lower than 97% of Healthcare companies in India.
Owes vs Owns
0.48×Lyka Labs Limited owes ₹0.48 for every ₹1 it owns (low), higher than 79% of Healthcare companies in India.
Dividend yield
NoneLyka Labs Limited does not currently pay a dividend.
Revenue growth
-7%Revenue fell 7% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Profit growth
LossLyka Labs Limited made a loss in the year to Mar 2026, after a profit the year before.
Profit margin
-7.8%Lyka Labs Limited lost ₹8 for every ₹100 of revenue.
Interest cover
Not coveredLyka Labs Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net debtLyka Labs Limited had ₹42 Cr more debt than cash (net debt) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Lyka Labs Limited: ₹293 Cr ÷ ₹92 Cr (31 Mar 2026) = 3.2.
What is Lyka Labs Limited's return on equity?
Lyka Labs Limited lost 9.7% of its shareholders' money over the last year, lower than 97% of Healthcare companies in India.
How much does Lyka Labs Limited owe compared with what it owns?
Lyka Labs Limited owes ₹0.48 for every ₹1 it owns (low), higher than 79% of Healthcare companies in India.
Does Lyka Labs Limited pay a dividend?
No. Lyka Labs Limited does not currently pay a dividend.
Is Lyka Labs Limited's revenue growing?
Revenue fell 7% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.